Home » Stocks » ZFGN

Zafgen, Inc. (ZFGN)

May 29, 2020 - ZFGN merged into LRMR
Stock Price: $0.990 USD 0.000 (0.00%)
Updated May 28, 2020 4:00 PM EDT
Market Cap 3.09M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 37.47M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 28, 2020
Last Price $0.990
Previous Close $0.990
Change ($) 0.000
Change (%) 0.00%
Day's Open 1.020
Day's Range 10.000 - 12.510
Day's Volume 4,323,149
52-Week Range 0.619 - 12.510


Hide News
GlobeNewsWire - 9 months ago

- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology...

Benzinga - 1 year ago

Clinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics into the com...

GlobeNewsWire - 1 year ago

Preliminary results from in vivo animal study not expected to warrant near-term resolution of clinical hold for ZGN-1061 Preliminary results from in vivo animal study not expected to warrant n...

Benzinga - 1 year ago

Shares of Zafgen Inc (NASDAQ: ZFGN) were tumbling below the psychological barrier of $2 in Thursday's session.

Benzinga - 1 year ago

Zafgem said it has planned to suspend to file an investigational new drug application, or IND, for its ZGN-1258, which it's evaluating for rare metabolic disorders including Prader-Willi syndr...

About ZFGN

Zafgen is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. (source: Wikipedia)

IPO Date
Jun 19, 2014
Jeffrey S. Hatfield
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements